Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity
| dc.contributor.author | Rozados, Viviana R. | |
| dc.contributor.author | Sánchez, Andrea M. | |
| dc.contributor.author | Gervasoni, Silvia I. | |
| dc.contributor.author | Berra, Héctor H. | |
| dc.contributor.author | Matar, Pablo | |
| dc.contributor.author | Scharovsky, O. Graciela | |
| dc.date.accessioned | 2012-08-28T18:23:35Z | |
| dc.date.available | 2012-08-28T18:23:35Z | |
| dc.date.issued | 2004-10 | |
| dc.description.abstract | BACKGROUND: Our aim was to investigate the clinical efficacy and toxicity of metronomic administration of low-dose cyclophosphamide (Cy) in lymphoma and sarcoma rat tumour models. METHODS: Adult inbred rats were challenged with lymphoma TACB and sarcoma E100 s.c. on day 0. Animals were divided into two groups: group I, control, injected with saline three times a week; and group II, treated with Cy 10 mg/kg three times a week, from day 10 until the tumour was non-palpable, or 5 mg/kg three times a week from day 7. Tumours were measured and animals were weighed twice weekly. Periodic blood samples were taken for determination of urea, creatinine, serum glutamic-oxaloacetic transaminase, lactate dehydrogenase and haematological parameters. RESULTS: The administration of low-dose Cy eradicated established rat lymphomas and sarcomas; there was neither metastatic growth nor recurrence at primary sites for 100% of the lymphomas and 83% of the sarcomas. In addition, the treatment did not cause weight loss, and was devoid of haematological, cardiac, hepatic and renal toxicity. CONCLUSIONS: Metronomic administration of Cy at low doses on a thrice weekly schedule to already grown rat lymphomas and sarcomas demonstrated itself to be a successful antitumour therapy that did not cause weight loss and was devoid of haematological, cardiac, hepatic and renal toxicity. | es |
| dc.description.peerreviewed | Peer reviewed | es |
| dc.format | application/pdf | |
| dc.identifier.citation | Rozados, V. R., Sánchez, A. M., Gervasoni, S. I., Berra, H. H., Matar, P., & Graciela, S. O. (2004). Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Annals of Oncology, 15, 10, 1543-1550. | es |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.uri | http://hdl.handle.net/2133/2013 | |
| dc.language.iso | en | es |
| dc.publisher | Oxford University Press | es |
| dc.relation.publisherversion | http://dx.doi.org/10.1093/annonc/mdh384 | es |
| dc.rights | openAccess | |
| dc.rights.text | © European Society for Medical Oncology | es |
| dc.subject | Cyclophosphamide | es |
| dc.subject | Lymphoma | es |
| dc.subject | Metronomic dosing | es |
| dc.subject | Sarcoma | es |
| dc.subject | Toxicity | es |
| dc.title | Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity | es |
| dc.type | artículo | |
| dc.type | publishedVersion | |
| dc.type | article |